These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 33353026)

  • 1. Cerebrospinal Fluid Penetration and Combination Therapy of Entrectinib for Disseminated
    Mayr L; Guntner AS; Madlener S; Schmook MT; Peyrl A; Azizi AA; Dieckmann K; Reisinger D; Stepien NM; Schramm K; Laemmerer A; Jones DTW; Ecker J; Sahm F; Milde T; Pajtler KW; Blattner-Johnson M; Strbac M; Dorfer C; Czech T; Kirchhofer D; Gabler L; Berger W; Haberler C; Müllauer L; Buchberger W; Slavc I; Lötsch-Gojo D; Gojo J
    J Pers Med; 2020 Dec; 10(4):. PubMed ID: 33353026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials.
    Doebele RC; Drilon A; Paz-Ares L; Siena S; Shaw AT; Farago AF; Blakely CM; Seto T; Cho BC; Tosi D; Besse B; Chawla SP; Bazhenova L; Krauss JC; Chae YK; Barve M; Garrido-Laguna I; Liu SV; Conkling P; John T; Fakih M; Sigal D; Loong HH; Buchschacher GL; Garrido P; Nieva J; Steuer C; Overbeck TR; Bowles DW; Fox E; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Demetri GD;
    Lancet Oncol; 2020 Feb; 21(2):271-282. PubMed ID: 31838007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Entrectinib: A Review in NTRK+ Solid Tumours and ROS1+ NSCLC.
    Frampton JE
    Drugs; 2021 Apr; 81(6):697-708. PubMed ID: 33871816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Entrectinib, a TRK/ROS1 inhibitor with anti-CNS tumor activity: differentiation from other inhibitors in its class due to weak interaction with P-glycoprotein.
    Fischer H; Ullah M; de la Cruz CC; Hunsaker T; Senn C; Wirz T; Wagner B; Draganov D; Vazvaei F; Donzelli M; Paehler A; Merchant M; Yu L
    Neuro Oncol; 2020 Jun; 22(6):819-829. PubMed ID: 32383735
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Entrectinib: A New Selective Tyrosine Kinase Inhibitor Approved for the Treatment of Pediatric and Adult Patients with NTRK Fusionpositive, Recurrent or Advanced Solid Tumors.
    Osman HM; Tuncbilek M
    Curr Med Chem; 2022; 29(15):2602-2616. PubMed ID: 34521321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
    Sartore-Bianchi A; Pizzutilo EG; Marrapese G; Tosi F; Cerea G; Siena S
    Expert Rev Anticancer Ther; 2020 May; 20(5):333-341. PubMed ID: 32223357
    [No Abstract]   [Full Text] [Related]  

  • 7. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
    Drilon A; Siena S; Dziadziuszko R; Barlesi F; Krebs MG; Shaw AT; de Braud F; Rolfo C; Ahn MJ; Wolf J; Seto T; Cho BC; Patel MR; Chiu CH; John T; Goto K; Karapetis CS; Arkenau HT; Kim SW; Ohe Y; Li YC; Chae YK; Chung CH; Otterson GA; Murakami H; Lin CC; Tan DSW; Prenen H; Riehl T; Chow-Maneval E; Simmons B; Cui N; Johnson A; Eng S; Wilson TR; Doebele RC;
    Lancet Oncol; 2020 Feb; 21(2):261-270. PubMed ID: 31838015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evolving role of entrectinib in treatment of
    Chawla N; Bui NQ; Seetharam M
    Future Oncol; 2021 Aug; 17(22):2835-2846. PubMed ID: 33896226
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
    Dziadziuszko R; Hung T; Wang K; Choeurng V; Drilon A; Doebele RC; Barlesi F; Wu C; Dennis L; Skoletsky J; Woodhouse R; Li M; Chang CW; Simmons B; Riehl T; Wilson TR
    Mol Oncol; 2022 May; 16(10):2000-2014. PubMed ID: 35338679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG).
    Desai AV; Robinson GW; Gauvain K; Basu EM; Macy ME; Maese L; Whipple NS; Sabnis AJ; Foster JH; Shusterman S; Yoon J; Weiss BD; Abdelbaki MS; Armstrong AE; Cash T; Pratilas CA; Corradini N; Marshall LV; Farid-Kapadia M; Chohan S; Devlin C; Meneses-Lorente G; Cardenas A; Hutchinson KE; Bergthold G; Caron H; Chow Maneval E; Gajjar A; Fox E
    Neuro Oncol; 2022 Oct; 24(10):1776-1789. PubMed ID: 35395680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety exposure-response analyses of entrectinib in patients with advanced or metastatic solid tumors.
    Mercier F; Djebli N; González-Sales M; Jaminion F; Meneses-Lorente G
    Cancer Chemother Pharmacol; 2022 Mar; 89(3):363-372. PubMed ID: 35118559
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of
    Liu D; Offin M; Harnicar S; Li BT; Drilon A
    Ther Clin Risk Manag; 2018; 14():1247-1252. PubMed ID: 30050303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Profile of entrectinib and its potential in the treatment of ROS1-positive NSCLC: evidence to date.
    Facchinetti F; Friboulet L
    Lung Cancer (Auckl); 2019; 10():87-94. PubMed ID: 31572036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Case Report: A case of complete response to entrectinib in
    Moriyama E; Nagasu S; Tanaka T; Shimotsuura Y; Ono T; Umeno H; Akiba J; Kawahara A; Fujita F; Kawaguchi T; Miwa K
    Front Oncol; 2023; 13():1247435. PubMed ID: 37601665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Entrectinib resistance mechanisms in ROS1-rearranged non-small cell lung cancer.
    Ku BM; Bae YH; Lee KY; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Invest New Drugs; 2020 Apr; 38(2):360-368. PubMed ID: 31124056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance Profile and Structural Modeling of Next-Generation ROS1 Tyrosine Kinase Inhibitors.
    Keddy C; Shinde P; Jones K; Kaech S; Somwar R; Shinde U; Davare MA
    Mol Cancer Ther; 2022 Feb; 21(2):336-346. PubMed ID: 34907086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements.
    Delgado J; Pean E; Melchiorri D; Migali C; Josephson F; Enzmann H; Pignatti F
    ESMO Open; 2021 Apr; 6(2):100087. PubMed ID: 33735800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid Tumors.
    Demetri GD; De Braud F; Drilon A; Siena S; Patel MR; Cho BC; Liu SV; Ahn MJ; Chiu CH; Lin JJ; Goto K; Lee J; Bazhenova L; John T; Fakih M; Chawla SP; Dziadziuszko R; Seto T; Heinzmann S; Pitcher B; Chen D; Wilson TR; Rolfo C
    Clin Cancer Res; 2022 Apr; 28(7):1302-1312. PubMed ID: 35144967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningeal "Lazarus Response" to Lorlatinib in a ROS1-Positive NSCLC Patient Progressing to Entrectinib.
    Facchinetti F; Levy A; Ammari S; Naltet C; Lavaud P; Aldea M; Vasseur D; Planchard D; Besse B
    Cancer Manag Res; 2021; 13():2805-2810. PubMed ID: 33814929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential treatments with TRK inhibitors in a patient with NTRK fusion-positive sarcoma: A case report.
    Kubota Y; Kawano M; Iwasaki T; Itonaga I; Tsumura H; Kaku N; Tanaka K
    Medicine (Baltimore); 2023 Dec; 102(49):e36232. PubMed ID: 38065851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.